As predictors of greater benefit, the authors suggested PD-L1 ≥ 10% (ORR 50.0% vs. 10.7%), a tumor mutational burden (TMB) ≥ 9.9 mut/Mb (ORR 75.0% vs. 16.1%), and/or high microsatellite instability (MSI-H) [11]. This evidence concerns the gene CD274 and neoplasm.